{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:02:50Z","timestamp":1788271370104,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Diabetes mellitus (DM) is a global health problem, and it has become a shocking threat in the contemporary era. The objective of this study was to analyze the safety of sotagliflozin in patients with DM systematically and intuitively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>On November 15, 2021, literature retrieval was performed on PubMed, Web of Science, EBSCO, and Cochrane libraries. The meta-analysis results included genital mycotic infection, related-to-acidosis events, and other related adverse events, including diarrhea, severe nocturnal hypoglycemia event, and volume depletion. In addition, a subgroup analysis was also conducted based on different doses of sotagliflozin. Moreover, the patient-treated years analyzed in the study were 12 weeks, 24 weeks, and 52 weeks, respectively, for type 1 diabetes, and were 12 weeks, 22 weeks, and 52 weeks, respectively, for type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results of this meta-analysis illustrated that sotagliflozin could increase the risk of genital mycotic infection for patients with T1D and T2D (RR: 3.49, 95% Cl: 2.54-4.79, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; RR: 2.83, 95% Cl: 2.04-3.93, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; respectively). In addition, the subgroup analysis showed that the drug doses that could increase the risk of genital mycotic infection were 400 mg and 200 mg (RR: 3.63, 95% Cl: 2.46-5.36, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; RR: 3.21, 95% Cl: 1.84-5.62, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; respectively) in T1D. Moreover, sotagliflozin could increase the risk of events related to acidosis in the patients of T1D, including acidosis-related adverse events, positively adjudicated diabetic ketoacidosis, acidosis-related event, and diabetic ketoacidosis (RR: 7.49, 95% Cl: 3.20-17.52, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; RR: 6.05, 95% Cl: 2.56-14.30, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; RR: 4.83, 95% Cl: 3.13-7.45, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; RR: 8.12, 95% Cl: 3.06-21.52, p &amp;lt; 0.001; respectively). In the patients of T2D, sotagliflozin could not increase the risk of DKA (RR: 1.30, 95% Cl: 0.34-4.99, p = 0.70). About serious of acidosis-related adverse events, positively adjudicated diabetic ketoacidosis (DKA) and acidosis-related event, the included studies were not reported for T2D patients. As for the other related adverse events, sotagliflozin was found to be a risk factor for diarrhea and volume depletion in T1D patients (RR: 1.44, 95% Cl: 1.09-1.90, p = 0.01; RR: 2.50, 95% Cl: 1.33-4.69, p &amp;lt; 0.01; respectively) and T2D patients (RR: 1.44, 95% Cl: 1.26-1.64, p &amp;lt; 0.001; RR: 1.25, 95% Cl: 1.07-1.45, p &amp;lt; 0.01; respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This meta-analysis showed that the adverse events of sotagliflozin were tolerable to patients with DM, in terms of the incidence of genital mycotic infection, related-to-acidosis events, diarrhea, volume depletion, and severe nocturnal hypoglycemia events. In addition, the subgroup analysis of sotagliflozin dosage is considered to have great clinical significance for future guidance of sotagliflozin application in patients with DM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.968478","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:15:45Z","timestamp":1664176545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Feifei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"112523","DOI":"10.1016\/j.ejmech.2020.112523","article-title":"An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent","volume":"204","author":"Bhattacharya","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S269","DOI":"10.1089\/dia.2018.0081","article-title":"Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care","volume":"20","author":"Danne","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz258","article-title":"Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption","volume":"105","author":"Powell","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14271","article-title":"Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index \u2265\u200927\u2009kg\/m(2)","volume":"23","author":"Danne","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14127","article-title":"Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2","volume":"22","author":"Rodbard","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0342","article-title":"HbA(1c) and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: The European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13645","article-title":"Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of type 1 and type 2 diabetes mellitus","volume":"35","author":"Sims","year":"2018","journal-title":"Diabetic medicine: J Br Diabetic Assoc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S144556","article-title":"The journey from gene knockout to clinical medicine: telotristat and sotagliflozin","volume":"13","author":"Rendell","year":"2019","journal-title":"Drug Design Dev Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14555","article-title":"Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis","volume":"24","author":"Avgerinos","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102888","DOI":"10.1016\/j.critrevonc.2020.102888","article-title":"Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis","volume":"147","author":"Gu","year":"2020","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2019.1656262","article-title":"Comparison of quality of life and nutritional status of between roux-en-Y and billroth-I reconstruction after distal gastrectomy: A systematic review and meta-analysis","volume":"72","author":"Du","year":"2020","journal-title":"Nutr Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13825","article-title":"Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12\u2009weeks: The inTandem4 trial","volume":"21","author":"Baker","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/dia.2020.0079","article-title":"Effects of sotagliflozin combined with intensive insulin therapy in young adults with poorly controlled type 1 diabetes: The JDRF sotagliflozin study","volume":"23","author":"Bode","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14513","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2149","article-title":"Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: A pooled analysis of 24-week continuous glucose monitoring data from the inTandem program","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7326\/M21-0651","article-title":"Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: A randomized trial","volume":"174","author":"Szarek","year":"2021","journal-title":"Ann Internal Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1479164121995928","DOI":"10.1177\/1479164121995928","article-title":"Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2","volume":"18","author":"Rodbard","year":"2021","journal-title":"Diabetes Vasc Dis Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020951928","article-title":"Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors","volume":"55","author":"Engelhardt","year":"2021","journal-title":"Ann Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","article-title":"Safety of sodium-glucose Co-transporter 2 inhibitors","volume":"124","author":"McGill","year":"2019","journal-title":"Am J Cardiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1167570","article-title":"Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes","volume":"128","author":"Arakaki","year":"2016","journal-title":"Postgraduate Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3810\/pgm.2013.05.2650","article-title":"Genital mycotic infections in patients with diabetes","volume":"125","author":"Nyirjesy","year":"2013","journal-title":"Postgraduate Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cmet.2018.09.011","article-title":"Lymphocyte-derived exosomal MicroRNAs promote pancreatic \u03b2 cell death and may contribute to type 1 diabetes development","volume":"29","author":"Guay","year":"2019","journal-title":"Cell Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2042018819890527","DOI":"10.1177\/2042018819890527","article-title":"A review of sotagliflozin for use in type 1 diabetes","volume":"10","author":"Nuffer","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101071","DOI":"10.1016\/j.molmet.2020.101071","article-title":"SGLT2 is not expressed in pancreatic \u03b1- and \u03b2-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans","volume":"42","author":"Chae","year":"2020","journal-title":"Mol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","article-title":"SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels","volume":"19","author":"Suga","year":"2019","journal-title":"Mol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000423","article-title":"SGLT inhibition: a possible adjunctive treatment for type 1 diabetes","volume":"25","author":"Akturk","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1793961","article-title":"An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes","volume":"21","author":"Chatzopoulos","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0924","article-title":"Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: A pooled analysis of the inTandem 1 and 2 studies","volume":"43","author":"Peters","year":"2020","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1939679","article-title":"Using adjuvant pharmacotherapy in the treatment of type 1 diabetes","volume":"22","author":"Sj\u00f6holm","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"l1328","DOI":"10.1136\/bmj.l1328","article-title":"Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials","volume":"365","author":"Musso","year":"2019","journal-title":"BMJ (Clinical Res ed)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0157","article-title":"Sotagliflozin added to optimized insulin therapy leads to lower rates of clinically relevant hypoglycemic events at any HbA1c at 52 weeks in adults with type 1 diabetes","volume":"21","author":"Danne","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26036","article-title":"Molecular interaction of anti-diabetic drugs with acetylcholinesterase and sodium glucose Co-transporter 2","volume":"118","author":"Shakil","year":"2017","journal-title":"J Cell Biochem"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.968478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:15:49Z","timestamp":1664176549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.968478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":39,"alternative-id":["10.3389\/fendo.2022.968478"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.968478","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"article-number":"968478"}}